These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 29900589)
1. Mineral and bone disorders in conventional hemodialysis: Challenges and solutions. Hamano T Semin Dial; 2018 Nov; 31(6):592-598. PubMed ID: 29900589 [TBL] [Abstract][Full Text] [Related]
2. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study. Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432 [TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism. Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A Nephron; 2018; 139(4):286-292. PubMed ID: 29879701 [TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
6. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571 [TBL] [Abstract][Full Text] [Related]
7. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States. Hall R; Platt A; Wilson J; Ephraim PL; Hwang AS; Chen A; Weiner DE; Boulware LE; Pendergast J; Scialla JJ; Clin J Am Soc Nephrol; 2020 Nov; 15(11):1603-1613. PubMed ID: 33046525 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491 [TBL] [Abstract][Full Text] [Related]
9. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Bernardor J; De Mul A; Bacchetta J; Schmitt CP Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027 [TBL] [Abstract][Full Text] [Related]
10. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study. Yamamoto J; Nakazawa D; Nishio S; Ishikawa Y; Makita M; Kusunoki Y; Nagai S; Fujieda Y; Takahata M; Yamada K; Yamamura T; Yotsukura A; Saito M; Shimazaki M; Atsumi T Ther Apher Dial; 2020 Apr; 24(2):146-153. PubMed ID: 31210004 [TBL] [Abstract][Full Text] [Related]
11. Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues? Jamal SA; Hodsman AB Semin Dial; 2011; 24(1):12-5. PubMed ID: 21299630 [TBL] [Abstract][Full Text] [Related]
12. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L. Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334 [TBL] [Abstract][Full Text] [Related]
13. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436 [TBL] [Abstract][Full Text] [Related]
14. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323 [TBL] [Abstract][Full Text] [Related]
15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Zhai CJ; Yang XW; Sun J; Wang R Int Urol Nephrol; 2015 Mar; 47(3):527-35. PubMed ID: 25399356 [TBL] [Abstract][Full Text] [Related]